Physician profile
Chester Mark Robachinski
NPI 1285697573
$1,131,105.60
in general payments reported to CMS, 2019-2025
23 companies · $272K in 2025
The $272K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $39K · 2021: $73K · 2022: $186K · 2023: $236K · 2024: $207K · 2025: $272K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $479K · Travel and Lodging: $91K · Consulting Fee: $87K · Honoraria: $34K · Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $479,438.00 |
| Travel and Lodging | $91,054.50 |
| Consulting Fee | $86,713.75 |
| Honoraria | $34,100.00 |
| Food and Beverage | $22,616.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $427,966.43 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223,565.10 | 2020-2025 | Caplyta |
| Alkermes, INC. | $96,313.99 | 2019-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $90,998.51 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $75,317.94 | 2023-2025 | Auvelity |
| Abbvie INC. | $64,474.39 | 2021-2025 | Vraylar |
| Allergan, INC. | $63,224.21 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $34,078.93 | 2019-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19,231.31 | 2019-2025 | Rejoyn, Rexulti |
| Janssen Scientific Affairs, LLC | $19,198.61 | 2022-2025 | Spravato, Invega Sustenna, Ponvory |
| Sunovion Pharmaceuticals INC. | $5,727.74 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $5,073.03 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Eisai INC. | $4,901.02 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $379.41 | 2019-2022 | |
| Tris Pharma INC | $226.25 | 2024-2025 | Onyda Xr, Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $129.78 | 2022 | |
| Gilead Sciences, INC. | $112.71 | 2019 | |
| Viiv Healthcare Company | $51.97 | 2024 | Apretude |
| Lundbeck LLC | $38.74 | 2020-2023 | Rexulti |
| Shire North American Group INC | $36.80 | 2019 | |
| Sage Therapeutics, LLC | $24.18 | 2023 | |
| Biogen, INC. | $18.50 | 2022 | |
| Sumitomo Pharma America, INC. | $16.05 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Robachinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.